|
Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415. |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Pfizer; Roche; Sanofi |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; MSD; Roche |
Consulting or Advisory Role - Bayer; Janssen-Cilag; MSD Oncology; Roche |
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; Janssen-Cilag |
|
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck Sharp & Dohme; Pfizer; Roche |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck Sharp & Dohme; Pfizer; Roche |
Research Funding - Janssen Oncology |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Merck Sharp & Dohme; Roche |
|
|
Honoraria - Merck Sharp & Dohme; Zodiac Pharma |
Research Funding - AstraZeneca/MedImmune (Inst); Janssen-Cilag (Inst); Merck Serono (Inst); MSD Oncology (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen |
Research Funding - Bayer; Janssen; Medivation; Myovant Sciences; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Roche |
|
|
No Relationships to Disclose |
|
David Queiroz Borges Muniz |
Other Relationship - Janssen; Pfizer |
|
|
No Relationships to Disclose |
|
|
Other Relationship - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen-Cilag |
|
|
|
|
Taiane Francieli Rebelatto |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS Brazil; Janssen |
Research Funding - Janssen (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS Brazil; Ipsen; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Roche/Genentech; Sanofi/Aventis |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS Brazil; ipsen; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Roche/Genentech |
Research Funding - Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Merck Sharp & Dohme |